Using measures of disease progression to determine therapeutic effect: a sirens' song - PubMed (original) (raw)
Review
. 2006 Aug 1;48(3):434-7.
doi: 10.1016/j.jacc.2006.03.050. Epub 2006 Jul 12.
Affiliations
- PMID: 16875965
- DOI: 10.1016/j.jacc.2006.03.050
Free article
Review
Using measures of disease progression to determine therapeutic effect: a sirens' song
Christopher B Granger et al. J Am Coll Cardiol. 2006.
Free article
Abstract
With an increasing burden of cardiovascular disease and many promising novel treatments in development, the need for efficient systems to evaluate treatments has never been greater. To understand whether a treatment should be used in practice, we need to know whether it makes patients live longer, feel better, prevents adverse events, or does these things with better tolerability or lower cost. But therapeutic development is expensive, inefficient, and is generally focused on short-term treatment effects, rather than on prevention and on long-term impact. Could measures of disease progression, combined with trends on clinical outcomes and post-marketing surveillance to assess safety, serve as the foundation for therapeutic development? Experience and principles of clinical research tell us no. Especially in the field of heart failure, numerous treatments have appeared promising based on disease markers, yet caused harm when tested in studies that assessed clinical outcomes. The intersection of complex human disease, intended and unintended targets of therapy, and overall risk and benefit make it impossible to accurately predict the effect on clinical outcomes based on impact on a disease marker. While reliable measures of disease progression are important to guide which treatments to study in trials, clinical outcome trials must remain the basis for informing clinicians on which treatments improve clinical outcomes. Improved reliability and capacity require the development of more efficient clinical trial methods, streamlined regulatory processes, rational use of privacy protection, leveraging of electronic medical records, and recruitment of a larger proportion of the clinical community to participate in clinical trials.
Comment in
- Efficacy and safety in clinical trials.
Cohn JN. Cohn JN. J Am Coll Cardiol. 2007 Feb 13;49(6):729; author reply 729. doi: 10.1016/j.jacc.2006.11.015. Epub 2007 Jan 26. J Am Coll Cardiol. 2007. PMID: 17291941 No abstract available.
Similar articles
- Efficacy and safety in clinical trials in cardiovascular disease.
Cohn JN. Cohn JN. J Am Coll Cardiol. 2006 Aug 1;48(3):430-3. doi: 10.1016/j.jacc.2006.01.083. Epub 2006 Jul 12. J Am Coll Cardiol. 2006. PMID: 16875964 Review. - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese. - How to anticipate the assessment of the public health benefit of new medicines?
Massol J, Puech A, Boissel JP; Participants inRound Table No 7, Giens XXII. Massol J, et al. Therapie. 2007 Sep-Oct;62(5):427-35. doi: 10.2515/therapie:2007071. Epub 2008 Jan 19. Therapie. 2007. PMID: 18206104 - Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Alexander KP, et al. Circulation. 2007 May 15;115(19):2549-69. doi: 10.1161/CIRCULATIONAHA.107.182615. Circulation. 2007. PMID: 17502590 Review. - [Controlled randomized clinical trials].
Jaillon P. Jaillon P. Bull Acad Natl Med. 2007 Apr-May;191(4-5):739-56; discussion 756-8. Bull Acad Natl Med. 2007. PMID: 18225427 French.
Cited by
- Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
Becker RE, Greig NH, Giacobini E. Becker RE, et al. J Alzheimers Dis. 2008 Oct;15(2):303-25. doi: 10.3233/jad-2008-15213. J Alzheimers Dis. 2008. PMID: 18953116 Free PMC article. Review. - Biomarkers in heart failure: a clinical review.
Rocchiccioli JP, McMurray JJ, Dominiczak AF. Rocchiccioli JP, et al. Heart Fail Rev. 2010 Jul;15(4):251-73. doi: 10.1007/s10741-008-9123-9. Epub 2008 Dec 3. Heart Fail Rev. 2010. PMID: 19051010 Review.